Cholesterol management strategies: LDL under 1.4, plaque regression & PCSK9 for extreme risk

Speaker

Andrew (surname unclear on ASR; host thanks “Andrew” at close) — QCG lipid / cardiology update tied to the cardiac case-meeting Mr BS narrative. Discloses Amgen sponsorship of the meeting; states no personal benefit.

Referenced faculty

Charles Chow (plaque biology / CT); Alex (CVD risk calculator / case host) from the companion cardiac case session.

Session context

Otter id wsHpuy0DAREyaNpHg9D42JCFpCU · title Cholesterol Management Strategies · ~26.8 min (1606 s). Companion: cardiac-case-meeting.

Key messages for GPs

• After an event aim LDL <1.4 mmol/L and >50% reduction from baseline (ESC 2025 framing; Australian 2023 direction similar). Extreme / recurrent risk may aim ~1.0.
• Lower for longer: ~1 mmol/L LDL drop ≈ 20% RRR CV events and ~10% all-cause mortality at 5 years in the large datasets quoted.
• ~50% of patients miss even PBS-style thresholds; best practice under 1.4 is harder still — combination therapy is normal for Mr BS phenotypes.
• Diet/exercise remodel plaque and cut events; they only move LDL ~10–20%. Medicines move the needle from 4 → 1s.
• Stack: high-intensity statin (~50%) + ezetimibe (~+25%) + PCSK9 (evolocumab often >60%; inclisiran ~50%).
• Counsel SAMS honestly; rechallenge; many “intolerances” are nocebo (SAMSON-style data). Repatha remains an option if oral therapy fails or is refused.

Shifting LDL goals

Thirty years ago population goals sat under 3.4, then under 2.6, then 1.8 for high risk. Therapy evolved from niacin/resins through high-intensity statins to PCSK9 after FOURIER (evolocumab / Repatha, ~2017), with novel orals and long-acting agents still arriving. ESC 2025: post-event <1.4 plus >50% from baseline — an index of 2 should not stop at 1.6–1.7. Extreme risk (recurrent events like Mr BS) under ~1.0. Australian 2023 guidance mirrors the downward march.

Biologically normal & plaque regression

Population averages are not biological normals (same story as BMI and BP). Hunter-gatherer and most mammal total cholesterols sit below modern average LDLs. Australian mean TC ~5.4. When LDL falls under 1.8 — more convincingly under 1.4 — intravascular ultrasound / imaging shows plaque regression and quieter inflammatory biology (linking to Charles Chow’s soft-plaque talk). GLAGOV-era Repatha work (Australian patients enrolled) saw regression begin ~1.8 and become consistent <1.4. 1990s primary-prevention trials (WOSCOPS, Scandinavian/ASCOT-era, US Air Force) already showed very low events when LDL sat under ~1.8. Ages 40–54 with LDL <1.4: essentially 0% positive calcium in the slide set shown — rising steeply as LDL climbs.

Cholesterol-years & lifetime risk

LDL is causative for plaque. Humans uniquely live past 50 among most mammals — heterozygous FH (~1/250) can persist because reproduction precedes typical event age. Homozygous FH → events in 20s–30s; heterozygous (Mr BS phenotype: LDL >5 + premature family disease) → 40s–50s; average LDL → later life; genetically low LDL → often spared. Father dead 53 / grandfather 48 is “the writing on the wall” — modifiable with a pill.

Short-term calculators may show only 3–5% five-year risk in a 40-something — still high with kids and peak career — while lifetime risk approaches certainty untreated. Overseas tools emphasise lifetime risk; hope Australian calculators catch up. Healthy ageing: “working into the 90s shaking hands” vs bypass in the 40s. Once atherosclerotic events occur, prognosis never fully resets — ~20% of MI survivors return within a year; recurrent events more often fatal. Primary prevention in GP land is where the biggest bang for buck sits (prevention paradox: most events from the large low/intermediate pool).

The treatment gap

Australian non-STEMI 12-month mortality ~5%. About half of patients miss LDL targets; PBS economic thresholds (>1.8) are not best-practice (<1.4). More comorbidities → lower aims (sometimes under 1.0). Post-MI average presentation LDL ~3.0; at 6–10 weeks many still >1.8 even on statin; ezetimibe shifts the curve; many still need PCSK9 for <1.4. Only ~60% take pills ≥80% of the time — non-adherence ≈ higher death; antihypertensives often taken more reliably than statins.

How to get to target

Mechanisms: every cell makes cholesterol; liver clears excess via LDL receptors into bile. Statins ↓ hepatic synthesis → ↑ receptors. Ezetimibe breaks enterohepatic absorption → ↑ receptors. PCSK9’s only job is lysosomal destruction of LDL receptors — block it (mAb) or silence its RNA (inclisiran) → more receptors → lower LDL.

Example from LDL 5.5: high-intensity statin → ~2.8; + ezetimibe → ~1.9 (still progressing plaque — as on Ben’s 12-month imaging); + PCSK9 → ~0.8. Recheck lipids every 4–6 weeks (drugs work before 4 weeks); PBS may think in 3-month blocks — closer follow-up keeps titration alive. Phone follow-up practice described.

Statin intolerance & nocebo

Lancet-scale review across ~500k trial patients: few proven statin side effects; many product-insert symptoms lack causal evidence. Known: diabetes risk ~1/1000 (dose-related, not LDL-related); muscle symptoms ~5% (similar on placebo); serious myopathy <1/10,000; LFT issues ~1/1000 (swap agent). SAMSON n-of-1: blinded statin vs placebo vs nothing — identical symptom logging on statin and placebo in many; some successfully rechallenged; some feel unwell every day regardless.

Counsel up front: look for big muscle-group “hit by a bus” aches (shoulders/quads), not finger/joint pain. Empower stop → restart lower dose / other brand / night dosing. Social media misinformation (statins, vaccines, paracetamol myths) takes logarithmic energy to refute — personalise with imaging (“you have disease”) rather than bludgeoning.

PCSK9 / Repatha practicalities

• Fortnightly self-pen (~15 s); refrigerate; room temp up to 30 days.
• ~51,000 patients / 15 years safety story in talk; injection-site reactions ~1/200; FOURIER ~15% RRR (less than “naive” 20% because residual risk after events); extended follow-up ~1.1% absolute CV death reduction at 5+ years quoted.
• Ebbinghaus cognitive substudy: no cognitive harm at mean LDL ~0.9 (including 0–0.5 subgroup).
• Self-fund ~$3,500/year with Amgen every-third-dose co-pay mentioned; many willing to pay to avoid tablets.
• PBS streamlined authority: LDL >1.8 after CV event + specialist involvement — put “appropriate for PCSK9 / streamlined authority” in letters so GPs can act. Statin-intolerant pathway: document trials of alternatives.
• VESALIUS (ASR: “Visalia”) primary-prevention high-risk data discussed as recent: mean age ~66, LDL ~2.1, ~12,000 patients — evolocumab cut events and all-cause death at 5 years in the summary given.

Clinic checklist

1. Name the target out loud: <1.4 after events; ~1.0 extreme; >50% from baseline.
2. Start (low then uptitrate) atorvastatin/rosuvastatin; co-prescribe ezetimibe early.
3. Recheck lipids 4–6 weekly until at goal; phone between visits if needed.
4. Counsel SAMS + nocebo; rechallenge before labelling “intolerant forever.”
5. If still >1.8 post-event (or refuses statin): PCSK9 — PBS letter wording or self-fund discussion.
6. Use calcium/CTCA as precision tools so the conversation is about visible disease, not abstract risk.

allcpd.drkotha.com · directory